Modulatory Effects of 1,25-Dihydroxyvitamin D3 on Human B Cell Differentiation

1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) can modulate immune responses, but whether it directly affects B cell function is unknown. Patients with systemic lupus erythematosus, especially those with antinuclear Abs and increased disease activity, had decreased 1,25(OH)2D3 levels, suggesting that vitamin D might play a role in regulating autoantibody production. To address this, we examined the effects of 1,25(OH)2D3 on B cell responses and found that it inhibited the ongoing proliferation of activated B cells and induced their apoptosis, whereas initial cell division was unimpeded. The generation of plasma cells and postswitch memory B cells was significantly inhibited by 1,25(OH)2D3, although the up-regulation of genetic programs involved in B cell differentiation was only modestly affected. B cells expressed mRNAs for proteins involved in vitamin D activity, including 1α-hydroxylase, 24-hydroxylase, and the vitamin D receptor, each of which was regulated by 1,25(OH)2D3 and/or activation. Importantly, 1,25(OH)2D3 up-regulated the expression of p27, but not of p18 and p21, which may be important in regulating the proliferation of activated B cells and their subsequent differentiation. These results indicate that 1,25(OH)2D3 may play an important role in the maintenance of B cell homeostasis and that the correction of vitamin D deficiency may be useful in the treatment of B cell-mediated autoimmune disorders.

[1]  H. Pols,et al.  Vitamin D , 1928, Calcified Tissue International.

[2]  W. Grant,et al.  Epidemiology of disease risks in relation to vitamin D insufficiency. , 2006, Progress in biophysics and molecular biology.

[3]  S. Harris,et al.  Vitamin D and African Americans. , 2006, The Journal of nutrition.

[4]  S. Shaftman,et al.  Vitamin D deficiency in systemic lupus erythematosus. , 2006, Autoimmunity reviews.

[5]  M. Cohen-Lahav Vitamin D decreases NFB activity by increasing IB levels , 2006 .

[6]  P. Lipsky,et al.  IL-21 Induces Differentiation of Human Naive and Memory B Cells into Antibody-Secreting Plasma Cells1 , 2005, The Journal of Immunology.

[7]  S. Nicosia,et al.  Suppression of Death Receptor-mediated Apoptosis by 1,25-Dihydroxyvitamin D3 Revealed by Microarray Analysis* , 2005, Journal of Biological Chemistry.

[8]  C. Mathieu,et al.  Immunoregulation by 1,25-dihydroxyvitamin D3: Basic concepts , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  M. Aringer,et al.  New treatments for SLE: cell-depleting and anti-cytokine therapies. , 2005, Best practice & research. Clinical rheumatology.

[10]  A. Rolink,et al.  Transcriptional networks in developing and mature B cells , 2005, Nature Reviews Immunology.

[11]  M. Schurgers,et al.  MANAGEMENT OF THERAPY-RESISTANT SYSTEMIC LUPUS ERYTHEMATOSUS WITH RITUXIMAB: REPORT OF A CASE AND REVIEW OF THE LITERATURE , 2005, Acta clinica Belgica.

[12]  K. Calame,et al.  Regulation of plasma-cell development , 2005, Nature Reviews Immunology.

[13]  B. Baslund,et al.  Vitamin D3 metabolism in patients with rheumatic diseases: Low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus , 1995, Clinical Rheumatology.

[14]  Wei Liu,et al.  Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. , 2004, Endocrinology.

[15]  J. Pers,et al.  Dysfunctional B cells in systemic lupus erythematosus. , 2004, Autoimmunity reviews.

[16]  L. Adorini,et al.  A Vitamin D Analog Down-Regulates Proinflammatory Chemokine Production by Pancreatic Islets Inhibiting T Cell Recruitment and Type 1 Diabetes Development1 , 2004, The Journal of Immunology.

[17]  S. Tangye,et al.  Divide and conquer: the importance of cell division in regulating B‐cell responses , 2004, Immunology.

[18]  I. Sanz,et al.  B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. , 2004, Arthritis and rheumatism.

[19]  S. Nicosia,et al.  p27Kip1 Stabilization and G1 Arrest by 1,25-Dihydroxyvitamin D3 in Ovarian Cancer Cells Mediated through Down-regulation of Cyclin E/Cyclin-dependent Kinase 2 and Skp1-Cullin-F-box Protein/Skp2 Ubiquitin Ligase* , 2004, Journal of Biological Chemistry.

[20]  P. Lipsky,et al.  Correlation of circulating CD27high plasma cells and disease activity in systemic lupus erythematosus , 2004, Lupus.

[21]  R. Wood,et al.  DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. , 2004, Physiological genomics.

[22]  C. Bingham,et al.  Racial, ethnic, and geographic disparities in rates of knee arthroplasty. , 2004, The New England journal of medicine.

[23]  P. Kelleher Autoantibodies before the clinical onset of systemic lupus erythematosus. , 2004, The New England journal of medicine.

[24]  P. Lipsky,et al.  B cell abnormalities in systemic lupus erythematosus , 2003, Arthritis research & therapy.

[25]  R Hal Scofield,et al.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus. , 2003, The New England journal of medicine.

[26]  Aristides G. Eliopoulos,et al.  Differential Regulation of Vitamin D Receptor and Its Ligand in Human Monocyte-Derived Dendritic Cells1 , 2003, The Journal of Immunology.

[27]  M. Worm,et al.  1α,25‐dihydroxyvitamin D3 inhibits anti‐CD40 plus IL‐4‐mediated IgE production in vitro , 2002 .

[28]  W. Liu,et al.  Vitamin D and Its Analog EB1089 Induce p27 Accumulation and Diminish Association of p27 with Skp2 Independent of PTEN in Pituitary Corticotroph Cells , 2002, Brain pathology.

[29]  Andreas Radbruch,et al.  Humoral immunity and long-lived plasma cells. , 2002, Current opinion in immunology.

[30]  M. Cogswell,et al.  Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. , 2002, The American journal of clinical nutrition.

[31]  C. Mathieu,et al.  Redirection of human autoreactive T-cells Upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). , 2002, Diabetes.

[32]  D. Joshua,et al.  Phenotyping primitive plasma cells , 2002, British journal of haematology.

[33]  C. Mathieu,et al.  The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. , 2002, Trends in molecular medicine.

[34]  L. Frati,et al.  Negative Regulation of CD95 Ligand Gene Expression by Vitamin D3 in T Lymphocytes1 , 2002, The Journal of Immunology.

[35]  Stevan R. Hubbard,et al.  IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA , 2002, Nature.

[36]  M. Worm,et al.  1alpha,25-dihydroxyvitamin D3 inhibits anti-CD40 plus IL-4-mediated IgE production in vitro. , 2002, European journal of immunology.

[37]  A. Algra,et al.  Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. , 2001, The Journal of rheumatology.

[38]  Huub F. J. Savelkoul,et al.  1α,25-Dihydroxyvitamin D3 Has a Direct Effect on Naive CD4+ T Cells to Enhance the Development of Th2 Cells1 , 2001, The Journal of Immunology.

[39]  R. Fischer,et al.  Knochendichte und 25-OH-Vitamin-D- Serumspiegel bei Patienten mit systemischem Lupus erythematodes , 2001, Zeitschrift für Rheumatologie.

[40]  M. Bourgeade,et al.  The Expression of p18INK4 and p27kip1 Cyclin-Dependent Kinase Inhibitors Is Regulated Differently During Human B Cell Differentiation1 , 2000, The Journal of Immunology.

[41]  N. Kouttab,et al.  Vitamin D-mediated gene regulation in phenotypically defined human B cell subpopulations. , 2000, Endocrinology.

[42]  C. Mathieu,et al.  Identification and immune regulation of 25‐hydroxyvitamin D‐1‐α‐hydroxylase in murine macrophages , 2000, Clinical and experimental immunology.

[43]  L. Adorini,et al.  1α,25-Dihydroxyvitamin D3 Inhibits Differentiation, Maturation, Activation, and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell Activation , 2000, The Journal of Immunology.

[44]  M. Vaisberg,et al.  Influence of cholecalciferol (vitamin D3) on the course of experimental systemic lupus erythematosus in F1 (NZBxW) mice , 2000, Journal of clinical laboratory analysis.

[45]  D. Gladman,et al.  Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. , 1999, Arthritis and rheumatism.

[46]  H. DeLuca,et al.  Current understanding of the molecular actions of vitamin D. , 1998, Physiological reviews.

[47]  G. Studzinski,et al.  Lowering of p27Kip1 levels by its antisense or by development of resistance to 1,25-dihydroxyvitamin D3 reverses the G1 block but not differentiation of HL60 cells , 1998, Leukemia.

[48]  M. Haussler,et al.  The Nuclear Vitamin D Receptor: Biological and Molecular Regulatory Properties Revealed , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[49]  M. Cippitelli,et al.  Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. , 1998, The Journal of clinical investigation.

[50]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[51]  D. Franklin,et al.  Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6. , 1997, Immunity.

[52]  N. Kouttab,et al.  1alpha,25-Dihydroxyvitamin D3 modulates CD38 expression on human lymphocytes. , 1996, Journal of immunology.

[53]  Wei Zhang,et al.  A new series of vitamin D analogs is highly active for clonal inhibition, differentiation, and induction of WAF1 in myeloid leukemia. , 1996, Blood.

[54]  C. Kwoh,et al.  Incidence of systemic lupus erythematosus. Race and gender differences. , 1995, Arthritis and rheumatism.

[55]  T. Hickish,et al.  The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. , 1993, British Journal of Cancer.

[56]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[57]  P. Lipsky,et al.  Generation of nondividing high rate Ig-secreting plasma cells in cultures of human B cells stimulated with anti-CD3-activated T cells. , 1992, Journal of immunology.

[58]  K. Bendtzen,et al.  The role of monocytes and T cells in 1,25-dihydroxyvitamin D3 mediated inhibition of B cell function in vitro. , 1991, Immunopharmacology.

[59]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.